Teva And Sanofi Fast-Track Anti-TL1A Phase 2b Trial For Inflammatory Bowel Disease

7/25/24 1:47:08 AM ET

$SNY

$TEVA

Biotechnology: Pharmaceutical Preparations

Health Care

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $SNY alert in real time by email

Enrollment acceleration drives earlier-than-anticipated data availability for this potentially best-in-class IBD treatment
Topline results for both UC and CD now anticipated in Q4 2024
Teva and Sanofi are collaborating to co-develop and co-commercialize duvakitug (anti-TL1A) for moderate-to-severe ulcerative colitis (UC) and Crohn's disease (CD) patients

Get the next $SNY alert in real time by email

Crush Q1 2026 with the Best AI Superconnector

Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

AI-Powered Inbox

Context-aware email replies

Strategic Decision Support

Get Started with Standout.work

Recent Analyst Ratings for
$SNY
$TEVA

Company	Date	Price Target	Rating	Analyst
Sanofi $SNY	2/12/2026		Buy → Neutral	BofA Securities
Sanofi $SNY	1/27/2026		Neutral	Citigroup
Sanofi $SNY	1/16/2026		Buy → Neutral	UBS
Sanofi $SNY	1/6/2026		Overweight → Equal Weight	Barclays
Teva Pharmaceutical Industries Limited $TEVA	12/9/2025	$35.00	Overweight	Barclays
Sanofi $SNY	12/9/2025		Buy → Neutral	Guggenheim
Sanofi $SNY	12/8/2025		Overweight → Neutral	Analyst
Teva Pharmaceutical Industries Limited $TEVA	12/5/2025	$35.00	Sector Outperform	Scotiabank

More analyst ratings

Teva And Sanofi Fast-Track Anti-TL1A Phase 2b Trial For Inflammatory Bowel Disease

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$SNY
$TEVA

Teva And Sanofi Fast-Track Anti-TL1A Phase 2b Trial For Inflammatory Bowel Disease

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$SNY
$TEVA

$SNY
$TEVA
Insider Trading

SEC Form 4 filed by EVP, Chief Financial Officer Kalif Eliyahu Sharon

SEC Form 4 filed by See "Remarks" Hughes Eric A

SEC Form 4 filed by See "Remarks" Sabag Mark

$SNY
$TEVA
SEC Filings

SEC Form 6-K filed by Sanofi

SEC Form 13F-HR filed by Sanofi

SEC Form 6-K filed by Sanofi

$SNY
$TEVA
Press Releases

Teva Canada Announces Approval of Expanded Indication of [Pr]AJOVY® (fremanezumab solution for subcutaneous injection), the First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine

Rezurock® now reimbursed in Ontario and British Columbia for people living with chronic graft-versus-host disease (GVHD)

Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential

$SNY
$TEVA
Insider Purchases

EVP, Chief Legal Officer Mcavoy David R. bought $20,988 worth of Ordinary Shares (1,113 units at $18.86), increasing direct ownership by 9% to 13,027 units (SEC Form 4)

$SNY
$TEVA
FDA approvals

March 28, 2025 - FDA Approves Novel Treatment for Hemophilia A or B, with or without Factor Inhibitors

February 14, 2025 - FDA Approves First Rapid-Acting Insulin Biosimilar Product for Treatment of Diabetes

FDA Approval for SOLIQUA 100/33 issued to SANOFI-AVENTIS US

$SNY
$TEVA
Analyst Ratings

Sanofi downgraded by BofA Securities

Citigroup initiated coverage on Sanofi

Sanofi downgraded by UBS

$SNY
$TEVA
Financials

Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential

Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Teva Releases Q4 2025 Aide Memoire

$SNY
$TEVA
Leadership Updates

Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma's Biggest Challenges

ITM Appoints Annette Breunig as Chief People Officer

The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?

$SNY
$TEVA
Large Ownership Changes

SEC Form SC 13G filed by Teva Pharmaceutical Industries Limited

Amendment: SEC Form SC 13G/A filed by Sanofi

SEC Form SC 13G filed by Sanofi

Teva And Sanofi Fast-Track Anti-TL1A Phase 2b Trial For Inflammatory Bowel Disease

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $SNY$TEVA

Teva And Sanofi Fast-Track Anti-TL1A Phase 2b Trial For Inflammatory Bowel Disease

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $SNY$TEVA

$SNY$TEVA Insider Trading

SEC Form 4 filed by EVP, Chief Financial Officer Kalif Eliyahu Sharon

SEC Form 4 filed by See "Remarks" Hughes Eric A

SEC Form 4 filed by See "Remarks" Sabag Mark

$SNY$TEVA SEC Filings

SEC Form 6-K filed by Sanofi

SEC Form 13F-HR filed by Sanofi

SEC Form 6-K filed by Sanofi

$SNY$TEVA Press Releases

Teva Canada Announces Approval of Expanded Indication of [Pr]AJOVY® (fremanezumab solution for subcutaneous injection), the First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine

Rezurock® now reimbursed in Ontario and British Columbia for people living with chronic graft-versus-host disease (GVHD)

Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential

$SNY$TEVA Insider Purchases

EVP, Chief Legal Officer Mcavoy David R. bought $20,988 worth of Ordinary Shares (1,113 units at $18.86), increasing direct ownership by 9% to 13,027 units (SEC Form 4)

$SNY$TEVA FDA approvals

March 28, 2025 - FDA Approves Novel Treatment for Hemophilia A or B, with or without Factor Inhibitors

February 14, 2025 - FDA Approves First Rapid-Acting Insulin Biosimilar Product for Treatment of Diabetes

FDA Approval for SOLIQUA 100/33 issued to SANOFI-AVENTIS US

$SNY$TEVA Analyst Ratings

Sanofi downgraded by BofA Securities

Citigroup initiated coverage on Sanofi

Sanofi downgraded by UBS

$SNY$TEVA Financials

Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential

Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Teva Releases Q4 2025 Aide Memoire

$SNY$TEVA Leadership Updates

Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma's Biggest Challenges

ITM Appoints Annette Breunig as Chief People Officer

The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?

$SNY$TEVA Large Ownership Changes

SEC Form SC 13G filed by Teva Pharmaceutical Industries Limited

Amendment: SEC Form SC 13G/A filed by Sanofi

SEC Form SC 13G filed by Sanofi

Recent Analyst Ratings for
$SNY
$TEVA

Recent Analyst Ratings for
$SNY
$TEVA

$SNY
$TEVA
Insider Trading

$SNY
$TEVA
SEC Filings

$SNY
$TEVA
Press Releases

$SNY
$TEVA
Insider Purchases

$SNY
$TEVA
FDA approvals

$SNY
$TEVA
Analyst Ratings

$SNY
$TEVA
Financials

$SNY
$TEVA
Leadership Updates

$SNY
$TEVA
Large Ownership Changes